加速经上皮角膜交联治疗进展性圆锥角膜:一项为期12个月的前瞻性研究
本研究纳入19例(30眼)进展性圆锥角膜日本患者,行加速经上皮角膜交联(紫外线A照射3分钟、辐照度30 mW/cm²),随访12个月。术中及术后无并发症,全部30眼完成随访;12个月时最大角膜曲率、平均角膜曲率和最薄角膜厚度显著下降,最佳矫正视力显著改善,其余指标无显著变化。
要点
- 加速经上皮角膜交联治疗进展性圆锥角膜12个月内无术中及术后并发症。
- 12个月时最大角膜曲率(p<0.0001)、平均角膜曲率(p=0.003)和最薄角膜厚度(p=0.002)显著下降。
- 12个月时最佳矫正视力显著改善(p=0.001),其余检查指标无显著变化。
核心结论
- 加速经上皮角膜交联与并发症无关,12个月随访的临床结果可评价。
研究设计与样本
- 前瞻性研究,纳入19例(16例男性、3例女性)进展性圆锥角膜患者的30眼,平均年龄24.9±7.0岁(范围16-38岁)。
- 全部患眼接受紫外线A照射3分钟、辐照度30 mW/cm²,随访至术后12个月。
主要发现
- 无术中或术后并发症,全部30眼完成随访。
- 术后12个月最大角膜曲率显著下降(p<0.0001)、平均角膜曲率显著下降(p=0.003)、最薄角膜厚度显著下降(p=0.002)、最佳矫正视力显著改善(p=0.001),其余指标无显著变化。
- 交联后疼痛或异物感出现在最初2天,所有病例持续时间不超过1周。
关键数值与推荐
- 紫外线A照射参数为3分钟、辐照度30 mW/cm²。
- 随访时点为术后第1天、1周、2周、1个月、3个月、6个月和12个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To evaluate the clinical results of accelerated transepithelial corneal cross-linking (CXL) in Japanese patients with progressive keratoconus (KCN). METHODS: Thirty eyes of 19 patients (16 male, 3 female patients) with progressive KCN were included. The mean age was 24.9±7.0 (range 16-38) years. All patients received ultraviolet A radiation for 3 min at an irradiance of 30 mW/cm2. Patients were followed up on the first day, at 1 week and 2 weeks, and at 1 month, 3 months, 6 months and 12 months postoperatively. Clinical examinations included measures of uncorrected visual acuity, best corrected visual acuity (BCVA), average keratometry (AveK), maximum keratometry (Kmax), central corneal thickness, thinnest corneal thickness (TCT), endothelial cell density, intraocular pressure and non-mydriatic indirect fundus examination. Patients were asked to report any pain or discomfort at each visit. RESULTS: There were no intraoperative or postoperative complications. All 30 eyes finished the follow-up. After 12 months, there was a significant decrease in Kmax (p<0.0001), AveK (p=0.003) and TCT (p=0.002), and a significant improvement in BCVA (p=0.001). There were no other significant changes. Pain or foreign-body sensation following CXL appeared in the first 2 days, but lasted no more than 1 week in all cases. CONCLUSIONS: There were no complications associated with accelerated transepithelial corneal CXL, and the clinical outcomes were appraisable in a 12-month follow-up. TRIAL REGISTRATION NUMBER: UMIN000009372.
引用
- Aixinjueluo W, Usui T, Miyai T, et al. Accelerated transepithelial corneal cross-linking for progressive keratoconus: a prospective study of 12 months. Br J Ophthalmol. 2017. PMID: 28057642. doi:10.1136/bjophthalmol-2016-309775
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。